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Abstract
Background: Chemoresistance is the main obstacle to cure in most malignant diseases. Anthracyclines are among the main
drugs used for breast cancer therapy and in many other malignant conditions. Single parameter analysis or global gene
expression profiles have failed to identify mechanisms causing in vivo resistance to anthracyclines. While we previously
found TP53 mutations in the L2/L3 domains to be associated with drug resistance, some tumors harboring wild-type TP53
were also therapy resistant. The aim of this study was; 1) To explore alterations in the TP53 gene with respect to resistance
to a regular dose epirubicin regimen (90 mg/m2 every 3 week) in patients with primary, locally advanced breast cancer; 2)
Identify critical mechanisms activating p53 in response to DNA damage in breast cancer; 3) Evaluate in vitro function of Chk2
and p14 proteins corresponding to identified mutations in the CHEK2 and p14(ARF) genes; and 4) Explore potential CHEK2 or
p14(ARF) germline mutations with respect to family cancer incidence.
Methods and Findings: Snap-frozen biopsies from 109 patients collected prior to epirubicin (as preoperative therapy were
investigated for TP53, CHEK2 and p14(ARF) mutations by sequencing the coding region and p14(ARF) promoter methylations.
TP53 mutastions were associated with chemoresistance, defined as progressive disease on therapy (p= 0.0358; p= 0.0136
for mutations affecting p53 loop domains L2/L3). Germline CHEK2 mutations (n = 3) were associated with therapy resistance
(p= 0.0226). Combined, mutations affecting either CHEK2 or TP53 strongly predicted therapy resistance (p= 0.0101; TP53
mutations restricted to the L2/L3 domains: p= 0.0032). Two patients progressing on therapy harbored the CHEK2 mutation,
Arg95Ter, completely abrogating Chk2 protein dimerization and kinase activity. One patient (Epi132) revealed family cancer
occurrence resembling families harboring CHEK2 mutations in general, the other patient (epi203) was non-conclusive. No
mutation or promoter hypermethylation in p14(ARF) were detected.
Conclusion: This study is the first reporting an association between CHEK2 mutations and therapy resistance in human
cancers and to document mutations in two genes acting direct up/down-stream to each other to cause therapy failure,
emphasizing the need to investigate functional cascades in future studies.
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Introduction
Chemoresistance is the main obstacle to cure in most
malignancies, including breast cancer. While adjuvant chemo-
therapy may reduce the hazard rate of relapse by about one third
in breast cancer patients [1], the majority among patients
harboring micro- metastases are not cured by today’s standards.
Considering patients harboring distant metastases, resistance and
therapy failure inevitably occurs, in general over a time period of
less than one year for each individual regimen [2].
Despite extensive experimental research [3], little data are
available considering chemoresistance in vivo. For anthracycline
therapy in breast cancer, topoisomerase-II amplifications have
been associated with a dose-responsiveness different from what is
observed in non-amplified tumors [4,5]. Several studies have tried
to generate ‘‘prediction profiles’’ based on gene expression
microarrays [6,7,8], however, none of the different profiles
generated expressed a sensitivity suitable for clinical applications,
or have been successfully reproduced by others (see references to
original works in [9] and [10]).
p53 (the protein encoded by the TP53 gene) plays a key role in
executing DNA-damage induced apoptosis and growth arrest [11].
Previously, our group reported mutations in the zink-binding
domains L2 (codons 163–195) and L3 (codons 236–251) of p53
critical to DNA binding [12] to be associated with but not fully
predictive for resistance to chemotherapy with a low-dose weekly
anthracycline [13] or a mitomycin plus 5-fluoro-uracil containing
[14] regimen. Similar findings were reported by another group [15].
In contrast, others reported TP53 mutations to predict sensitivity to
a dose-dense epirubicin-cyclophosphamide regimen [16].
The finding that some tumors harboring wild-type TP53may be
resistant to anthracycline therapy lead us to postulate that other
genes involved in the p53 pathway could be mutated in these
tumors [3]. p53 is activated by post-translational modifications,
and the protein is phosphorylated at multiple amino acids [17].
Phosphorylation at Ser 20 (Ser 23 in mice) by the Chk2 protein
(coded by the CHEK2 gene) in response to DNA damage activates
p53 by inhibiting binding to, and deactivation by, the MDM2
(Mouse Minute 2 homolog; HDM2) protein [18,19,20]. While
experimental studies have suggested a critical role of Chk2 in
activating p53 apoptotic response to genotoxic stress [21,22],
others claim Chk2 to be dispensable for p53 activation with
respect to apoptosis as well as growth arrest [23]. Following an
initial report of a CHEK2 germline mutation in a family filling the
characteristics of a Li-Fraumeni syndrome (LFS) [24], recent
papers have suggested germline mutations in CHEK2 to be
associated with a moderately increased risk of breast and colon
cancers (see references in [25]). Recently, we discovered a somatic,
nonsense CHEK2 mutation in a single patient expressing resistance
to doxorubicin low dose therapy [26].
A second mechanism of p53 activation is through p14(ARF) (p19
in mice) function. p14(ARF) does not phosphorylate p53, but
inhibits MDM2 dependent p53 degradation through direct
MDM2 binding. While p14(ARF)-mediated p53 activation has
been linked to oncogene-induced p53 activation and, in general,
considered not involved in response to DNA damage (see
references in [27]), p14(ARF) may be activated through the
E2F1/retinoblastoma pathway [28]. Importantly, two recent
studies revealed lack of p19 (mouse homologue of human
p14(ARF)) function in mice to inhibit p53 tumor suppressor
function in response to ionizing radiation as well as DNA
damaging agents [29,30].
The aim of this study was 1) to explore alterations in the TP53
gene with respect to resistance to a regular dose epirubicin
regimen (90 mg/m2 body surface every 3 week) in patient with
primary, locally advanced, breast cancer; 2) To explore defects in
potential mechanisms activating p53 in response to DNA damage
in breast cancer as a cause of drug resistance in wild-type tumors.
To do so, we sequenced the complete coding regions for the
CHEK2 and p14(ARF) genes and analyzed for p14(ARF) promoter
hypermetylations; 3) Evaluate in vitro function of potential Chk2
and p14(ARF) protein translates corresponding to identified
mutations in the CHEK2 and p14(ARF) genes; 4) Identify potential
TP53, CHEK2 and p14(ARF) mutations to be germline, explore the
incidence of different cancers among affected relatives with respect
to specific mutations. By comparing in vitro characteristics of
specific mutations to drug sensitivity and family cancer risk
syndromes, this may add to our understanding of the importance
of these gene cascades executing response to DNA damage versus
tumor suppression activity.
Analyzing tumor samples from a total of 109 primary locally
advanced breast cancer patients treated with epirubicin 90mg/3
weekly, we found TP53 mutations affecting the L2/L3 domains or
protein dimerization, as well as non-functional CHEK2 mutations
abrogating dimerization and phosphorylation, to be associated with
therapy resistance; no mutation or promoter hypermethylations of
the p14(ARF) gene was discovered. Our findings suggest a critical role
for Chk2 with respect to DNA-damage-dependent p53 activation
and resistance to anthracycline therapy in human breast cancer.
Materials and Methods
Patients
A total of 223 patients with locally advanced non-inflammatory
breast cancer (T3-4 and/or N2) were randomly allocated to
primary treatment either with epirubicin 90 mg/m2 or paclitaxel
200 mg/m2. The primary aim of the study was identification of
markers predicting drug resistance to the regimens. Thus, the
reason for randomizing patients was not for effect comparison, but
to achieve similar patient cohorts in the two arms. Based on the
findings of a clinical lack of cross-resistance between anthracy-
clines and taxane therapies in breast cancer [31], we hypothesized
the mechanisms of resistance to be different between the two
compounds. While the analysis of tumor samples from the
paclitaxel is ongoing, we here report our findings from the
patients allocated to the epirubicin arm.
The epirubicin arm included a total of 109 patients (age 28 to
70 years, median 51 years). Two patients were analyzed for gene
mutations but omitted from statistical analysis as protocol
violators; histopathological examination revealed one patient
(Epi089) to harbor a sarcomatoid tumor, while one patient
Epi232 was erroneously enrolled with stage II disease.
The study protocol was approved by the Regional Ethical
Committee (Norwegian Health Region III), including formal
Biobank registration in accordance to Norwegian law. The study
and protocol is registered under the Norwegian Social Science
Data services ((www.nsd/uib/personvern/database/), University
of Bergen project no 16297 and Helse Bergen project no 13025).
Each patient gave written informed consent.
Tissue Sampling
Before commencing chemotherapy, each patient had an
incisional tumor biopsy as described previously [14]. All tissue
samples were snap-frozen immediately on removal in the theatre.
Treatment Regime and Staging
Primary treatment consisted of epirubicin (90 mg/m2) admin-
istered as a 3-weekly schedule. Treatment was scheduled for four
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cycles unless progression occurred at an earlier stage. Clinical
response was assessed before each treatment cycle, and the final
response evaluated 3 weeks after the 4th cycle for overall response
classification. Because the protocol was implemented by October
1997 with patients enrolled between November 1997 and December
2003, responses were consistently graded by the UICC system [32]
and not the more recently implemented ‘‘RECIST’’ criteria [33].
Thus, responses were classified as CR (Complete Response,
complete disappearance of all tumor lesions), PR (Partial Response,
reduction $50% in the sum of all tumor lesions, calculated for each
as the product of the largest diameter and the one perpendicular to
it), PD (Progressive Disease, increase in the diameter product of any
individual tumor lesion by$25%), and SD (Stable Disease, anything
between PR and PD). To analyze for the predictive value of the
different parameters, similar to our previous studies [13,14] we
compared PD tumors (non responders) with the combined group of
tumors classified as SD/PR/CR (responders); the reason for this
approach is discussed in detail elsewhere [34]. Median follow-up
time was defined from patient inclusion in the study up to October
31, 2006. Deaths attributable to causes other than breast cancer were
treated as censored observations.
All patient records were subject to central audit for response
classification (by E.L., B.Ø. and P.E.L.). Response classifications
were completed and approved without any knowledge about result
from laboratory analysis.
RNA Purification
Total RNA was purified by Trizol (Life Technologies, Inc.)
extraction from snap-frozen tissue samples according to manufac-
turer’s instructions. After extraction, the RNA was dissolved in
100 ml of DEPC treated ddH2O. cDNA was synthesized by
reverse transcription using Transcriptor reverse transcriptase
(Roche), according to the manufacturer’s protocol.
DNA Purification
Genomic DNA from tumor biopsies and blood lymphocytes was
isolated using QIAamp DNA Mini kit (Qiagen, Chatsworth, CA)
according to the manufacturer’s protocol.
Mutation Analysis
All mutational analysis was performed blinded to clinical data.
Mutations in TP53, CHEK2 and p14(ARF) genes were analyzed by
PCR (or nested PCR) amplification and sequencing of PCR
product, or by cloning of PCR products and sequencing of the
resulting plasmids (all primers described in Table 1). Cloning was
performed using the TOPO TA Cloning kit (Invitrogen).
Sequencing of clones was performed until at least 10 different
sequences covered all parts of the CHEK2 coding sequence. DNA
sequencing was carried out directly on 1 ml PCR product or
plasmid using Big Dye terminator mix (Applied Biosystems).
Capillary gel electrophoresis, data collection, and sequence
analysis were done on an automated DNA sequencer (ABI
3700). When a mutation was detected, the relevant exon was
amplified by PCR from genomic tumor DNA and DNA from
blood lymphocytes and sequenced for verification and germline
detection. (Primers described in Table 1).
Loss of Heterozygosity (LOH)
Loss of heterozygosity (LOH) in tumors with mutations in
CHEK2 was assessed using the microsatellite marker, D22S275,
which maps to intron 4 of CHEK2. LOH in tumors with mutation
in TP53 was assessed using two markers, one variable number
tandem repeat in intron 1 [35] and a CA repeat close to the TP53
gene [36]. Fluorescently end-labeled primers were used in the
PCR, and the PCR products were analyzed on an ABI 3700.
LOH was evaluated by comparing the allele peak-height ratios
from blood DNA and tumor DNA. A sample was scored as having
AI (Allelic Imbalance) when a reduction in peak height of one
allele in tumor sample was at least 18% compared with that of
blood DNA from the same patient [37].
Analysis of p14(ARF) promoter methylation
Genomic DNA was subjected to bisulphate conversion using the
CpGenome DNA Modification Kit (Intergen) according to the
manufacturer’s protocol. Both the unmethylated- and methylated-
specific PCRs were performed in 50 ml reaction mixes containing
2.5 U AmpliTaq Gold DNA Polymerase (Applied Biosystems), 16
PCR buffer, 1.5 mM MgCl2, 0.1 mM of each deoxynucleotide
triphosphate, 0.2 mM of each primer (Table 1) and 2 ml of
modified genomic DNA. Thermocycling conditions for both the
unmethylated- and methylated-specific PCRs were an initial step
of 5 minutes at 95uC followed by 35 cycles of 30 sec. at 94uC,
30 sec. at 60.5uC and 60 sec. at 72uC before a final elongation
step at 72uC for 7 min.
Chk2 Dimerisation
Chk2 mutant’s ability to form dimers with the wild-type protein
was investigated by immunoprecipitation. U-2-OS cells were co-
transfected with expression vectors expressing wild-type Chk2 with
N-terminal Xpr-tag (pcDNA4/HisMax, Invitrogen) and mutated
Chk2 forms with C-terminal V5-tag (pcDNA3.1/V5-His, Invitro-
gen). Transfection was performed using FuGene 6.0 transfection
reagent (Roche) according to the manufacturer’s instructions. Cells
were harvested in lysisbuffer (50 mM TrisHCl pH 8.0, 150 mM
NaCl, 0.5% NP40, 5 mM EDTA pH 8.0) 48 hours after
transfection. An aliquote of the cell lysate was harvested for
subsequent Chk2-mutant-V5 transfection verification. Samples
were further incubated with A/G Pluss Agarose beads (Santa Cruz
Biotechnology) at 4uC for 25 minutes before the beads were
removed by centrifugation at 5000g for 4 minutes and the samples
were incubated with 1.5 mg anti-V5 (Invitrogen) at 4uC for
90 minutes. Fresh A/G Pluss Agarose beads were added and the
samples were incubated for another 90 minutes at 4uC. The beads
were washed three times with 16PBS, before being separated on a
10% polyacrylamide gel and blotted on to a nitrocellulose
membrane. Chk2-wild-type-Xpr co-precipitated with Chk2-mu-
tant-V5 was detected through incubations with anti-Xpr antibody
(Invitrogen), HRP-conjugated secondary antibody and ECL
detection reagent (GE Healthcare).
Kinase Activity
Chk2 mutant’s ability to function as kinases was investigated
through an in vitro kinase assay. The V5 expression vectors used for
the dimerisation study were also used to express Chk2 mutants in
the kinase assay. U-2-OS cells were transfected using the FuGene
6.0 transfection reagent (Roche) according to the manufacturer’s
instructions. Cells were then incubated at 37uC in 5% CO2 and
humidified atmosphere. After 24 hours doxorubicin (Nycomed
Pharma) was added to the media to a final concentration of 50ng/
ml and the cells were further incubated for 24 hours before
harvest. 75 cm2 of 90% confluent cells were harvested in 500 ml
lysis buffer (50 mM HEPES, 150 mM NaCl, 10% glycerol, 0.5%
Triton X-100, 2 mM MgCl2, 5 mM EDTA), and the cytosol was
incubated for 90 minutes at 4uC with 50 ml 50% Glutathione
Sepharose beads (Amersham Biosciences) linked to anti-V5
antibody (Invitrogen). The beads were then washed twice with
lysisbuffer containing 500 mM NaCl and twice with kinase assay
Chk2 and p53 in Cancer Therapy
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buffer (50 mM HEPES, 10 mM MgCl2, 5 mM MnCl2, 2.5 mM
EGTA). The beads received 30 ml kinase assay buffer with 7.5 mM
cold ATP, 10 mCi 32P-gamma-ATP (GE Healthcare) and 2 mg
isolated Cdc25C peptide, and was incubated at 30uC for
30 minutes. Samples were separated on a 12.5% polyacrylamide
gel and blotted on to a nitrocellulose membrane. A radiosensitive
imaging plate was exposed to the membrane and the plate was
read in a FLA200 imager (Fuji).
The kinase assay described above was also used to determine
the Chk2 mutants’ kinase activity after co-transfection of each
Chk2 mutant and wild-type Chk2 in equal amounts.
Statistical Analysis
Statistical analysis was performed using the Primer of
Biostatistics system, version 5.0 [38]. The differences in the
distribution of TP53 and CHEK2 mutations among patients
revealing a PD and the responders were analyzed with use of
Fisher’s exact test. P-values are reported as accumulated two-
sided. Because of the limited time of the follow-up, no formal
statistical assessment of overall survival was performed. Relapse-
free survival was analyzed by the log-rank test. Details regarding
outcome in individual patients with mutations are shown in
Table 2 and 3 to make them available to the reader.
Results
TP53 Mutations and Response to Therapy
The TP53 mutations identified in the tumors of the patients
treated with epirubicin together with the clinical response to
therapy and follow-up data are presented in Table 2. Somatic
Table 1. PCR primers for amplification and sequencing of cDNA
TP53 Orientation CHEK2 Orientation
1.Round p53 ns2: 59-gac act ttg cgt tcg ggc Forward chk2s1: 59-atg tct cgg gag tcg gat g Forward
p53 nas2: 59-ctt gtt cag tgg agc ccc g Reverse chk2as1: 59-acc acg gag ttc aca aca cag Reverse
2.Round p53 frag1s: 59-gac acg ctt ccc tgg att ggc Forward chk2s3: 59-ctc ctc tac cag cac gat gc Forward
P53 frag4as: 59-cgc aca cct att gca agc aag gg Reverse chk2as2: 59-aga acc tgg ggt aga gct gtg Reverse
Sequencing primers p53 frag3s: 59-tgg ccc ctc ctc agc atc tta Forward chk2s3: 59-ctc ctc tac cag cac gat gc Forward
p53 frag2as: 59-ggt aca gtc aga gcc aac ctc Reverse chk2-7F: 59-atc atc ctt gca tca tca ag Forward
chk2-7R: 59-atc aat tcc aaa aca ata taa taa tc Reverse
p14
1.Round p14 f2: 59-cggcgagaacatggtgcg Forward
p14 r2: 59-ttcccgaggtttctcagagcc Reverse
2.Round p14 f2: 59-cggcgagaacatggtgcg Forward
p14 nest r: 59-tct ctg gtt ctt tca atc g Reverse
Sequencing primers p14 nest r: 59-tct ctg gtt ctt tca atc g Reverse
PCR primers for amplification and sequencing of genomic DNA
Exon 1 Chk2 ex1F 59-gtc ttg tgc ctt gaa act c Forward
Chk2 ex1R 59-cca cct ggt aat aca act tt Reverse
Exon 5 p53 ex5r 59-ctg ttc act tgt gcc ctg act tt Forward
p53 ex5r 59-gga atc aga ggc ctg ggg ac Reverse
Exon 6 p53 ex6f 59-gac gac agg gct ggt tgc Forward
p53 ex6r 59-gcc act gac aac cac cct taa Reverse
Exon 7 p53 ex7f 59-gct tgc cac agg tct ccc Forward
p53 ex7r 59-gca gag gct ggg gca ca Reverse
Exon 8 p53 ex8f 59-gga cct gat ttc ctt act gcc Forward
p53 ex8r 59-gtg aat ctg agg cat aac tg Reverse
Exon 9 p53 ex9f 59-caa gaa gcg gtg gag gag a Forward Chk2 ex9F 59-acg gct tac ggt ttc acc Forward
p53 ex9r 59-aac ggc att ttg agt gtt aga c Reverse Chk2 ex9R 59-caa gaa tct aca gga ata gcc Reverse
Exon 10 p53 ex10f 59-ctc ccc ctc ctc tgt tgc tg Forward
p53 ex10r 59-aag gca gga tga gaa tgg aat c Reverse
Sequencing primers Either forward or reverse primer were used Either forward or reverse primer were used
p14 Methylation spesific primers
Methylated p14_met s 59-gtg tta aag ggc ggc gta gc Forward
p14_met as 59-aaa acc ctc act cgc gac ga Reverse
Unmethylated p14_umet s 59-ttt ttg gtg tta aag ggt ggt gta gt Forward
p14_umet as 59-cac aaa aac cct cac tca caa caa Reverse
doi:10.1371/journal.pone.0003062.t001
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TP53 mutations were identified in 23 (21.5%) of the patients.
Normal tissue (WBC) was available from 18 of these for germline
characterization, revealing none of the mutations identified to be
germline alterations. Of the 23 mutations detected, 20 were
missense and 3 were nonsense. One mutation (del483CAT) has
not been reported previously either in breast cancer or in any
other tumor type (IARC database: http://www.iarc.fr/p53/).
Twelve of the mutations directly or indirectly affected the L2/L3
domains of the p53 protein (Table 2) previous found to predict a
poor prognosis [39] and drug resistance [14,40]. For statistical
comparison, mutation Gly325Ter (patient Epi215) located to the
tetramerization domain is grouped together with the mutations
affecting the L2/L3 domain, since this mutation leads to
truncation of the protein and with loss of tetramerization and
functional defects similar to L2/L3 mutations [41].
There was a statistical significant correlation between TP53
mutation status and lack of treatment response (PD) (Table 4;
p = 0.0358; Fisher exact test). When tumors harboring TP53
mutations affecting the p53 L2/L3 DNA-binding domains were
compared to those with wild-type TP53 or TP53 mutations outside
the L2/L3 domains, this correlation was further strengthened
(p = 0.0136).
The previously described TP53 polymorphism, Arg72Pro [42]
was detected in 31 (29%) of our patients. No correlation was found
between this polymorphism and lack of treatment response
(p=0.2750; Fisher exact test) or TP53mutational status (p=0.2024).
CHEK2 Mutations and Response to Therapy
Table 3 presents the patients with detected CHEK2 mutations
together with a description of the clinical response and follow up-
data. CHEK2 mutations were identified in three out of the 109
patients (2.8%). Notably, each of the CHEK2 mutations identified
was also present in patient lymphocyte DNA, confirming a
germline origin. The Arg95Ter (C283T) mutation is novel. This
mutation was present in two patients (Epi132 and Epi203) living in
different parts of Norway with no known family relationship.
However, linkage analysis using microsatellite markers (D22S275,
D22S272, D22S1172 and D22S423) suggested a common founder
mutation (data not shown). The C283T transition generates a
novel stop codon in exon 1 of CHEK2, leading to truncation of the
Table 3. Characteristics of CHEK2 mutants found and clinical data
Patient
Age
(Yrs)
Clinical
response Codon Exon
Nucleotide
change1
Amino
acid
change LOH
Protein
domain
Predicted
mutation EReceptor PReceptor T N M
Relapse-
free
Survival3
Site of
relapse
Overall
Survival^
Epi 151 57 PR 364 9 ATARACA IleRThr NI kinase
domain
missense Positive Positive 3 1 0 F60 A60
Epi 203 41 PD 95 1 CGARTGA ArgRTer AI nonsense Negative Negative 3 1 1 0 NA D9
Epi 132 44 PD 95 1 CGARTGA ArgRTer AI nonsense Positive Positive 5 2 0 *F60 A60
1, The bolded bases indicate the base change; T N M, TNM-classification, AJCC 2002 =UICC 2002, T, size or direct of the primary tumor; N, spread to regional lymph
nodes; M, distant metastasis; 3, ‘‘F’’ followed by a number indicates that the patient was free of disease at that number of months of follow-up. ‘‘R’’ followed by a
number indicates that the patient was alive at that number of months of follow-up but had suffered a relapse; ^, ‘‘A’’ followed by a number indicates that the patient
was alive at that number of months of follow-up. ‘‘D’’ followed by a number indicates that the patient died at that number of months of follow-up; AI, Allelic imbalance;
NI, Not informative; NA, Not available. ‘‘*’’ This patient subsequently relapsed with distant metastases at 64 months.
doi:10.1371/journal.pone.0003062.t003
Table 4. Clinical response in relation to different parameters
Clinical response Statistical significance
CR
(n=3)
PR
(n=50)
SD
(n=44)
PD
(n=10) P1 P2
TP53
Wild type (n = 84) 2 41 36 5
All mutations (n = 23) 1 9 8 5 0.0358 0.0488
Mutations affecting L2/L3 (n = 12) 1 5 2 4 0.0136 0.0439
CHEK2
Wildtype (n = 104) 3 49 44 8
All mutations (n = 3) 1 2 0.0226 0.0631
TP53+CHEK2*
All mutations in TP53+CHEK2 1 10 8 6 0.0101 0.0183
Mutations affecting TP53 L2/L3+CHEK2 1 6 2 5 0.0032 0.0165
P1 with regard to clinical response comparing CR+PR+SD versus PD
P2 with regard to clinical response comparing CR+PR versus PD
*One of the PD patients has got a mutation both in CHEK2 and TP53 (L2 domain), this has been taken into consideration under calculation of statistical significance
1P, with regard to clinical response comparing CR+PR versus PD; 2P, with regard to clinical response comparing CR+PR+SD versus PD; *, One of the PD patients has got a
mutation both in CHEK2 and TP53 (L2 domain), this has been taken into consideration under calculation of statistical significance.
doi:10.1371/journal.pone.0003062.t004
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Chk2 protein. LOH analysis indicated loss of the wild-type CHEK2
allele in the both tumors from the two patients harboring this
mutation (Epi132 and Epi203). Both these tumors were non-
responsive to epirubicin therapy (PD). In contrast, the third patient
with a germline CHEK2 mutation (patient Epi151; point mutation
at T1091C, Ile364Thr) had a partial response to epirubicin
therapy. This tumor was non-informative with respect to LOH.
Taking all CHEK2 mutations together, they predicted resistance to
epirubicin (p = 0.0226).
The previously described silent Glu84Glu (A252G) polymorphism
[24,43] in exon 1 was detected in two (1.9%) patients. No association
between this polymorphism and treatment response was recorded.
One of the tumors (Epi203) harboring the C283T substitution
(Arg95Ter) also harbored a somatic TP53 mutation in codon 175,
Arg175His, located in the L2 domain of p53 (Table 2). This
mutation was detected in another four of our patients treated with
epirubicin (Table 2). In addition, TP53 Arg175His mutation was
recorded in one patient of our previous study evaluating response
to doxorubicin [13]. The fact that none of the Arg175His patients
presented here or in our previous study revealed resistance to
therapy (PD) suggests this mutation may not cause resistance to
anthracyclines in breast cancers in vivo. Omitting the tumor
harboring both a CHEK2 and a TP53 mutation (patient Epi203)
from statistical analysis, Chk2 mutations (n = 2) were non-
significantly associated with therapy resistance (p= 0.1633). In a
previous study [26], however, we analyzed for CHEK2 mutation
status in relation to therapy outcome in a cohort of patients from
doxorubicin study [13]. In that study [26], we detected the
previously identified mutation Ile157Thr. In addition, we detected
a novel nonsense somatic mutation (1368InsA). This mutation was
associated with lack of function in vitro; moreover, it was associated
with drug resistance in vivo. Analyzing our material and this cohort
[26] together, (n = 160), CHEK2 mutations (n = 5 in total)
predicted for resistance to doxorubicin and epirubicin therapy
(p = 0.0123). Even though, excluding patient Epi203 (harboring
TP53 Arg175His and Arg95Ter CHEK2 mutation) as well as other
patients harboring TP53 L2/L3 mutations (n = 129), CHEK2
mutations (n = 4 in total) predicted for resistance to doxorubicin
and epirubicin therapy (p= 0.030).
TP53 and CHEK2 Mutations Combined and Response to
Therapy
Assuming that TP53 and CHEK2 mutations may substitute for
each other, we analyzed for the predictive effect of mutations in
both genes. The occurrence of a mutation affecting either CHEK2
or TP53 strongly predicted therapy resistance (p=0.0101; Fisher
exact test). When tumors harboring TP53-L2/L3 mutations and
CHEK2 mutations were compared with those wild-type or TP53
mutations outside the L2/L3 domain, the correlation was further
strengthened (p = 0.0032; Fisher exact test). The significance was
preserved when comparing patients with a PD to objective
responders (CR and PR) excluding patients with stable disease
(SD) from the statistical analysis (Table 4).
p14(ARF) Mutations and Promoter Methylations
Neither mutations nor polymorphisms in the coding region of
p14(ARF) were observed among the 107 patients analyzed.
Likewise, no promoter methylations were detected.
Influence of CHEK2 and TP53 Mutation Status on Relapse-
Free Survival
Because of the limited time of the follow-up, no formal statistical
assessment of overall survival was performed. Details regarding
outcome for individual patients with mutations are described in
Table 2 and 3 to make these data available to the reader. Relapse-
free survival is depicted in (Figure 1). Figure 1A shows relapse-free
survival for the patients with TP53 and CHEK2 mutations (all
mutations found) compared to patients without any TP53 or
CHEK2 mutations, no difference in relapse-free survival was
observed. Similar, no difference was seen when grouping TP53
mutations outside L2/L3 and CHEK2 mutation not affecting
kinase function (Ile364Thr) as wild-type (Figure 1B). Grouping
tumors harboring a mutation in L2/L3 together with CHEK2
mutations affecting kinase domain (Arg95Ter) in one group,
mutations outside TP53 L2/L3 and Ile364Thr as one group and
tumors without any found mutations in TP53 and CHEK2
separately, again no noticeably difference in relapse-free survival
were seen (Figure 1C). Notably, in addition to a short median
follow-up time, a total of 35 patients with a sub-optimal response
to epirubicin received subsequent treatment with paclitaxel, which
may have influenced the outcome.
CHEK2 Mutant’s Capability to Form Dimers
To investigate whether the identified CHEK2 mutations affect
the ability of the Chk2 protein to form dimers, co-transfection and
immunopresipitation of V5-tagged mutants and Xpress-tagged
wild-type Chk2 were performed using CHEK2 low-expressing U-2-
OS cells. As we identified the previously characterized CHEK2
germline mutants variants Arg117His (n = 2 and Ile157Thr (n= 1)
among patients allocated to primary treatment with paclitaxel in
our ongoing study, these mutants were evaluated together with
Arg95Ter and Ile364Thr. The results presented in Figure 2 show
that all Chk2 variants carrying a point mutation were able to form
dimers with wild-type Chk2, whereas the Arg95Ter variant was
not.
Kinase Activity of CHEK2 Mutants
To investigate whether the identified CHEK2 mutants retained
the wild-type kinase activity, an in vitro Chk2 kinase assay with
respect to Chk2 autophosphorylation and Cdc25 substrate
phosphorylation was performed. The U-2-OS cells were preferred
for this assay because they were previously found to express only
low levels of endogenous Chk2 [44]. This was confirmed by us
using an antibody recognizing endogenous protein (data not
shown). These cells have previously been used by other
investigators to study Chk2 kinase activity [44,45,46].
The two mutants Arg117Gly and Ile157Thr were previously
tested for in vitro kinase activity [47], but were both included here,
together with wild-type CHEK2 as controls. Compared to wild-
type Chk2, the Ile157Thr mutant retained wild-type kinase
activity. The mutant Ile364Thr showed partially reduced kinase
activity both in term of Cdc25-phosphorylation and autopho-
sphorylation (Figure 3). In contrast, the mutant Arg117Gly showed
strongly reduced kinase activity while the Arg95Ter mutant was
totally devoid of any Chk2 kinase activity. The activity recorded
for Ile157Thr and Arg117Gly was consistent with previously
reported results for these two mutants [47]. Notably, there was an
internal consistency with respect to percentage activity reduction
comparing individual mutants with respect to autophosphorylation
and phosphorylation of Cdc25 (Figure 3).
Since enzymatically active Chk2 exists as dimers, it was
important to determine the effect of Chk2 mutants on wild-
type/mutant heterodimer kinase activity. The effect on Chk2
kinase activities (Chk2 autophosphorylation and Cdc25 substrate
phosphorylation) of the individual mutants were therefore
determined after co-transfection with wild-type Chk2 as described
in Materials and Methods. The results from this co-transfection-
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Figure 1. Kaplan-Meyer analysis of the relapse-free survival of the patients according to mutations. WT, wild-type; TP53+CHEK2 mut, all
found mutations in TP53 and CHEK2; TP53 L2/L3+CHEK2 (Arg95Ter) mut, TP53 mutations affection L2/L3 domain and CHEK2 mutations affecting
kinase function; TP53+CHEK2 (Ile364Thr), mutations not affecting L2/L3 domains and CHEK2 mutations not affecting kinase function. Deaths due to
causes other than breast cancer are treated as censored observations. Each ‘‘+’’ mark represents the time one patient was censored. NS, Non
significant.
doi:10.1371/journal.pone.0003062.g001
Figure 2. Pulldown-assay for CHEK2 mutants. V5-tagged Chk2 mutants were co-expressed with Xpr-tagged wt-Chk2 in U-2-OS-cells and
immunoprecipitation was performed using anti-V5 antibody. Expression of the Chk2 mutants was monitored by anti-V5 based Western blot analysis
prior to immunoprecipitation (upper panel). The Chk2 mutant’s ability to dimerize with the wild-type protein was detected by anti-Xpr Western blot
analysis of the precipitate (lower panel).
doi:10.1371/journal.pone.0003062.g002
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Figure 3. Kinase activity of CHEK2 mutants. A) Level of Chk2 mutants immunoprecipitated from U-2-OS cells, used as input for kinase activity
assay, monitored by anti-V5 based Western blot analysis. B) Autoradiogram showing in vitro kinase activity of Chk2 mutants with respect to both
Chk2 autophosphorylation and Cdc25 phosphorylation. C) Kinase activity of CHEK2 mutants normalized for kinase-input, based on band intensities in
Figures 3A and B.
doi:10.1371/journal.pone.0003062.g003
Figure 4. Kinase activity of CHEK2mutant’s co-transfected with CHEK2 wild-type. A) Kinase assay input of V5-tagged mutant Chk2 and Xpr-
tagged wild-type Chk2, monitored by anti-V5 and anti-Xpr based Western blot analysis. B) Autoradiogram showing in vitro kinase activity (Chk2
autophosphorylation and Cdc25 phosphorylation) of Chk2 mutants with co-precipitated Chk2 wild-type.
doi:10.1371/journal.pone.0003062.g004
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kinase assay (Figure 4) were similar to those of the single-
transfection assay (Figure 3) except in the case of the Arg117Gly
mutant, which expressed a substantial kinase activity when
complexed with wild-type Chk2. This is consistent with previous
data indicating that the Arg117Gly mutant has neglectable kinase
activity itself but dimerizes efficiently to Chk2 wild-type without
strongly affecting the wild-type Chk2 activity. Hence, the activity
detected is probably caused by the co-transfected and co-
precipitated wild-type protein.
To rule out the possibility that endogenously expressed wild-
type Chk2 contributed to observed Arg117Gly kinase activity
shown in Figure 4, we compared the Arg117Gly variant activity in
the presence or absence of co-transfected wild-type Chk2 to the
activities of Arg95Ter under the same conditions. The Arg95Ter
variant does not form dimers with wild-type Chk2. As seen in
Figure 5, Arg117Gly, which forms dimers with Chk2 wild-type,
allows increased activity when co-transfected with wild-type as
compared to the corresponding activity for the Arg95Ter mutant.
The fact that Arg117Gly, when transfected alone, displays very
similar activity as Arg95Ter or negative control (background
levels), strongly indicates that the contribution of endogenous
Chk2, which, similarly to exogenously expressed wild-type Chk2
co-precipitate with Arg117Gly is non-significant.
Family Cancer Incidence in Relation to CHEK2 Germline
Mutations
Following an initial report of a family with a CHEK2 germline
mutation expressing an increased cancer incidence resembling the
Li-Fraumeni syndrome [24], recent studies have revealed the more
common CHEK2 mutations to be associated with a moderately
increased risk of breast and colorectal cancers. We hypothesized
that CHEK2 mutations having a detrimental effect on drug
sensitivity could be associated with a more aggressive, Li-Fraumeni
or a Li-Fraumeni-like (LFL) cancer syndrome [48]. Except from
the patient harboring the Ile364Thr mutation who did not have
any known congestion of cancer disease in the family, a detailed
assessment of family cancer history was performed for each patient
harboring a germline CHEK2 mutation. The family cancer
pedigrees are depicted in Figure 6.
While patients harboring CHEK2 germline mutations revealed
different types of cancers (mainly breast and tumors of the
gastrointestinal area) in their family, surprisingly, no distinct
pattern discriminating families harboring the Arg95Ter mutation
from the other CHEK2 mutated families could be identified. One
of them (Epi203), who inherited the mutation from her father’s
side of the family, had no accumulation of either breast or
colorectal cancer on that side. It should be noted, however, that
two brothers of her fathers mother had prostate cancer, and two
siblings of his father having hepatocellular carcinoma and bladder
cancer, respectively), while the other expressed a disease pattern
resembling what has been seen with the more common CHEK2
mutations, like del1100C [25].
Discussion
TP53 plays a key role as a tumor suppressor gene. Its protein
product activates processes such as growth arrest, DNA repair,
apoptosis and/or senescence in response to genotoxic damage as
well as oncogene activity [49,50]. Despite being extensively
studied, critical issues regarding regulation of the p53 protein
remain poorly understood, and conflicting evidence obtained in
different experimental systems make the clinical relevance of
experimental data questionable.
Chemoresistance is the main obstacle to cancer cure in most
malignancies, including breast cancer. Previously, we found TP53
mutations affecting the L2/L3 DNA binding domain to be
associated with lack of responsiveness to doxorubicin monotherapy
[13] as well as mitomycin and 5-fluoro-uracil in concert [14].
However, some tumors revealed therapy resistance despite
harboring wild-type TP53. Postulating that these tumors may
harbor genetic disturbances in genes playing a key role in the p53
pathway, we here sequenced TP53 along with CHEK2 and
p14(ARF), the latter two known to play a critical role as p53
activators, in tumors from 109 patients treated with epirubicin
monotherapy. Our results confirm TP53 mutations, in particular
those affecting the L2/L3 domains, to be associated with drug
resistance. Most importantly, we also found CHEK2 mutations
generating a non-functional protein in our in vitro assays to be
associated with drug resistance. In contrast, none of our tumors
harbored either mutations or expressed promoter hypermethyla-
tions affecting the p14.
Based on in vitro assays, we were able to classify the different
Chk2 mutants with respect to dimerization capability as well as
kinase activity (Chk2 autophosphorylation and Cdc25 substrate
phosphorylation). In addition, the kinase activities of the Chk2
wild-type/mutant complexes were monitored in co-transfection
experiments. Notably, each point mutation (except for Arg117Gly)
revealed similar relative kinase efficacy whether co-transfected
with wild-type Chk2 or not (Figure 3 and 4). Cells co-transfected
with Arg117Gly and wild-type Chk2 revealed kinase activity,
probably due to the contribution of the wild type protein in Chk2
mutant – wild-type heterodimers. In contrast, cells transfected with
Arg95Ter revealed no kinase activity whether co-transfected with
wild-type Chk2 or not, clearly distinguishing this mutation from
the others (Figure 3 and 5).
All in vitro assays were based on transfection of the U-2-OS cell
line, a cell line known to express wild-type Chk2 at low levels, and
previously used by other investigators to study Chk2 activity
[44,45,46]. Since we were not able to obtain satisfactory technical
quality of the kinase assay in cell lines negative for Chk2 (HCT 15
and HCT 116), we assessed potential background kinase activity
due to endogenous Chk2 by performing western blot analysis
revealing the endogenous levels of Chk2 in U-2-OS cells to be
non-significant compared to the exogenously expressed Chk2
levels (data not shown). We also performed a separate kinase assay,
Figure 5. Contribution of co-precipitated Chk2 wild-type to the
activity in the in vitro assays. Transfection of the Arg117Gly mutant
with and without Chk2 wild-type, along with Arg95Ter +/2 wild-type.
Arg117Gly, when transfected alone, does not display higher kinase
activity (Cdc25 phosphorylation) than Arg95Ter or negative control.
This strongly indicates that the contribution of endogenous Chk2 is
non-significant.
doi:10.1371/journal.pone.0003062.g005
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directly comparing the effect of binding partners for the
dimerizing Arg117Gly and the non-dimerizing Arg95Ter. This
assay also revealed the contribution of endogenous Chk2 to be
non-significant (Figure 5).
Taking our in vitro findings together with in vivo observations, our
present data confirm that the functionally defective CHEK2
Arg95Ter mutation, together with LOH, is associated with
resistance to anthracycline therapy. In contrast, the patient
harboring the Ile364Thr mutation, moderately reducing phos-
phorylation activity, responded well to therapy. The other
missense mutations; Arg117Gly and Ile157Thr were observed
among patients receiving paclitaxel therapy only; thus, their
influence on anthracycline sensitivity in vivo could not be
addressed. Yet, based on the finding that the Arg117Gly mutant
expressed no intrinsic activity, but readily dimerized to the wild-
type protein without abolishing its activity, we hypothesize that
this mutation and, probably, other yet unidentified CHEK2
mutations with a similar lack of intrinsic kinase activity, may
cause resistance to anthracycline therapy if combined with LOH
in breast cancer.
Our present findings have two major implications. First, we
confirm that mutations in genes encoding proteins located within
the same functional pathway may substitute for each other with
respect to drug sensitivity, revealing for the first time a functional
pathway critical to chemotherapy response in vivo. Second, the
identification of mutations in the CHEK2 but not in the p14(ARF)
gene in resistant tumors suggests that Chk2 mediated phosphor-
ylation of p53 is a critical event in executing anti-tumor effect as a
response to DNA damaging agents in breast cancer. This adds to
our understanding not only of the function of p53 but Chk2 as
well. p53 undergoes phosphorylation at multiple sites by different
kinases, including Chk2 [51]. While activation of the ATM leading
to direct (Ser 15) and Chk2-mediated (Ser 20) phosphorylation of
p53 is considered an important mechanism for triggering p53
activation in response to DNA damage [52], some reports suggest
ATM [53] and even Chk2 [23] to be redundant to this function.
Importantly, Chk2 has been shown capable of inducing ATM-
independent apoptosis in vitro [21]. While Chk2 phosphorylates
p53 at Ser 20, thereby stabilizing p53 by preventing MDM2
binding [19], Chk2 also phosphorylates p53 at six additional sites,
including Ser 313 and Ser 314 located in the nuclear localization
signal domain of p53 [51]. In addition, Chk2 phosphorylates other
important targets like BRCA1, Cdc25A and Cdc25C involved in
DNA repair, G1 and G2 arrest, respectively [54]. Despite the wide
range of known Chk2 substrates relevant for DNA repair and cell
cycle control, our present findings that CHEK2 mutations leading
to non-functional Chk2 protein may substitute for p53 mutations
strongly advocate a role for Chk2 with respect to drug sensitivity
executed through p53 activation.
Notably, one of the tumors (Epi203) with the Arg95Ter CHEK2
mutation in addition harbored a somatic TP53 mutation,
Arg175His, with allelic imbalance for the TP53 gene (Table 2).
Importantly, among another four patients in this study (Epi063,
Epi071, Epi087, Epi153) and one patient from our previous
doxorubicin protocol [13] harboring the Arg175His mutation
together with allelic imbalance for TP53, all five of these patients
responded to anthracycline therapy either with a partial response
or stable disease. In contrast, Epi132 and the only patient for
whom we previously identified a non-functional CHEK2 mutation
(1368InsA; coding for a non-functional protein translate with
cytoplasmic location [26]) expressed resistance to epirubicin and
doxorubicin, respectively. Arg175His is a p53 ‘‘hot-spot’’ struc-
tural mutation reported to have defects with respect to
transcriptional activation and also to negatively interact with
wild-type p53 [55]. While this mutation has been shown to
enhance chemoresistance upon transfection into p53 null Saos-2
cells [56], these osteosarcoma-derived cells may not necessarily be
representative for breast cancers in vivo. Recent evidence strongly
support p53 to be involved also in non-transcriptional mediated
apoptosis by interacting with the Bcl-2/Bax system [57], and
transcription-defect structural p53 mutants have been shown to
execute non-transcriptional apoptosis in experimental systems
[58]. Concomitant inactivation of Chk2 and p53 in breast cancer
has been recorded by others [59], and the finding that a somatic
mutation may generate a ‘‘growth advantage’’ in tumor cells
already harboring a germline CHEK2 mutation may not implicate
an effect on drug sensitivity in tumors not yet exposed to cytotoxic
compounds. Rather, it may indicate a growth advantage, probably
related to loss of p21 function. Notably, in a previous study we
found the p21 polymorphism G251A to be associated with an
increased risk of developing large breast cancers but to have no
effect on drug sensitivity [60], indicating that growth rate and drug
resistance may be regulated independently. Taken together, we
believe our findings advocate a role for Chk2 in executing cellular
response to anthracycline-induced DNA damage.
As mentioned above, removing TP53 mutated tumors including
the double-mutated Epi203 from statistical analysis, CHEK2
mutation status still predicted for resistance to anthracycline
therapy. In addition, removing the tumors harboring the
Arg175His mutation from the p53 ‘‘L2/L3’’ group strengthened
the correlation to lack of treatment response to epirubicin
(p = 0.0005).
Comparing the effects of mutations in the CHEK2 gene to TP53
mutations indirectly underlines the importance of the role of Chk2
to chemoresistance. Our present findings as well as results from
our previous studies [13,14] revealed that about 50% of the
patients with tumors harboring TP53 L2/L3 mutations to be non-
responders to primary therapy. In contrast, all our three patients
harboring a non-functional CHEK2 mutation (the two Arg95Ter
mutated patients here and our previous patient harboring the
1368InsA) expressed primary resistance to therapy. We previously
hypothesized that therapy response in tumors harboring TP53 L2/
L3 mutations could be due to redundant pathways acting in
concert [3]. Although no definite conclusion should be drawn from
a limited number of observation, the fact that Chk2 not only
phosphorylates p53 but also phosphorylates other substrates such
as Cdc25A and Cdc25C [54] and E2F1 in response to etoposide-
induced DNA damage [61] may indicate that inactivation of
redundant pathways could take place in parallel.
Figure 6. Pedigrees of the breast cancer cases with germline mutations in CHEK2. The index individuals initially screened are indicated with
arrows. All cancer patients marked in bold, and cancers are indicated by type and age at diagnosis. D followed by number indicates the age of death.
#, indicate that diagnosis could not be verified from medical documents.Mut2, indicates individuals tested negative for relevant mutations.Mut +,
indicates that individuals hold the relevant mutation. The trees have been altered to preserve anonymity, but the meaning of the report is not
affected by these alterations. BC, Breast cancer; BD, Blood disease; BLC, Bladder cancer; CC, Colon cancer; EC, Endometri cancer; GC, Gastric cancer;
HD, Heart disease; HL, Hodgkins Lymphoma; L, Lymphoma; LAC, Larynx cancer; LC, Lung cancer; LE, Leukemia; LEC, Liver cancer; OC, Ovarian cancer;
OL, Oral Lymphoma M; P, Parkinson; PC, Prostate cancer; SA, Sarcoma; SE, Seminom; SI, Carcinoid in small intestine; TBC, Tuberculosis.
doi:10.1371/journal.pone.0003062.g006
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The literature remains inconsistent with respect to whether the
border amino acids 163, 195, 236 and 251 should be included in
the p53 L2 and L3 domains [12]. Taking a conservative approach,
we classified patient Epi56, harboring a mutation in codon 163, as
a L2/L3 mutant. The patient harboring this mutation responded
to therapy (PR). If this mutation was classified as outside the L2
domain, our p-value had been strengthened from p=0.0136 to
p=0.0096.
Germline mutations in TP53 cause the Li-Fraumeni and Li-
Fraumeni-like cancer disposition syndromes. However, while the
germline and somatic mutations associated with these syndromes
reveal a preference for the same codons [48], TP53 mutations
affecting the DNA-binding domains seem associated with a poor
prognosis [62,63,64] and, in particular, drug resistance [14,40] in
breast cancer. Thus, tumor suppression and tumor cell response to
chemotherapeutics may involve different parts of p53 protein
function. Following an initial report identifying a CHEK2 mutation
in a family expressing characteristics of the Li-Fraumeni syndrome
[65], recent evidence has linked CHEK2 founder mutations to a
moderately increased risk of breast- and colorectal cancers with
some additional disposition for other malignancies as well [66].
However, cancer incidence and phenotypes did not reveal an
aggressive Li-Fraumeni or Li-Fraumeni-like tumor pattern.
Similar to the two patients in our paclitaxel treatment arm
harboring the rare but previously characterized mutation
Arg117Gly and the patient with the Ile157Thr mutation, they
expressed a moderately increased risk of breast and gastrointestinal
cancers (Fig. 6). Thus, CHEK2 resembles TP53 in as much as there
seems to be no direct correlation between effects of individual
mutations with respect to tumor suppression and drug resistance.
Our finding that TP53 mutations located to the DNA-binding
domains predicts drug resistance may indicate transcriptional
mechanisms to be involved in drug-induced cell death. p53
induced apoptosis has been associated with transcriptional
induction of genes including Puma and Noxa as well as Bax in
experimental systems [55,67,68]. Yet, recent evidence has revealed
p53 to induce apoptosis through non-transcriptional mechanisms
by direct protein interactions with members of the Bcl-2/Bax
system and mitochondrial release of cytochrom c [57,69]. In deed,
there is evidence that the DNA-binding domains, in particular the
L3 part of the protein, may be critical also to transcriptional-
independent apoptosis [70]. Of particular note is the finding that
Chk2 may regulate transcriptional-independent p53-mediated
apoptosis in response to DNA-damage created through ionizing
irradiation [71]. Interestingly, Krajewski et al [72] reported low
expression of Bax assessed by immunostaining to be associated
with a low response to chemotherapy in metastatic breast cancer.
Although no conclusion should be drawn at this stage, together
these findings are consistent with the challenging hypothesis that
transcription-independent activation of Bax following Chk2-
phosphorylation may represent a key pathway in p53 dependent
cell death in breast cancer in vivo.
p14 acts by releasing p53 from MDM2 binding, and has been
related to oncogene-induced p53 activation [73]. Recently, p14
was shown to affect p53 by additional mechanisms, including
acetylations [74], response to ionizing radiation in human
fibroblasts [75], and tumor-suppression following ionizing radia-
tion in mice [76,77]. These findings further links the retinoblas-
toma and p53 pathways [28]. As such, we believe the negative
finding with respect to its role in chemoresistance adds important
information.
Contrasting earlier findings by us and others [15], a recent study
revealed TP53mutations to be associated with increased likelihood
of having a complete response to chemotherapy [16]. These results
may not necessarily be at conflict. In the latter study, patients
received treatment with a ‘‘dose-dense’’ chemotherapy regimen; if
confirmed, the combined data may outline a therapeutic
indication for aggressive dose-dense therapy based on tumor
TP53/CHEK2 status.
So far attempts to identify single markers and, more recently,
gene expression arrays predicting chemoresistance have not
proved successful (see refs in [9,10]). The findings presented here
reveal for the first time defects in a functional gene cascade to be
associated with drug resistance in a human cancer in vivo.
Moreover, the findings are made in breast cancer, the most
frequent malignant disease among women in the industrialized
world, and relate to resistance to anthracyclines, the type of
cytotoxic compounds most frequently employed for this malig-
nancy.
While the only study we are aware of comparing TP53 mutation
status in primaries and their distant metastases suggested an
increasing fraction of tumors to express mutated TP53 during
progression [78], we do not know the potential contribution of
either TP53 or CHEK2 mutations to drug resistance in
micrometastases or in metastatic disease. Yet the finding that
one of our non-functional CHEK2 mutations associated with
chemoresistance (1368InsA) occurred as a somatic, not germline
mutation, suggest such mutations may be selected for during
tumor progression. We propose the findings presented here
provide important beacons identifying a functional pathway [3]
likely to be disturbed through different mechanisms in relation to
therapy resistance in advanced disease.
In conclusion, we believe our findings here that mutations in the
TP53 and CHEK2 genes each may cause resistance to anthracy-
cline therapy in primary tumors to have wide implications to
future research in this area. While results from experimental
systems are mandatory generating hypotheses, conflicting data
from in vitro studies underlines the pivotal role of identifying defects
associated with therapy resistance in vivo. Either through mutations
of the genes themselves, or inactivation of this functional cascade
through co-factors, we believe identification of the Chk2 – p53 axis
as critical to anthracycline therapy response provides a functional
clue for further investigations in this area.
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